Fig. 3
From: CKAP2L, a crucial target of miR-326, promotes prostate cancer progression
miR-326 targets CKAP2L and inhibits its expression. (A) The binding sites of miR-326 targeting CKAP2L were predicted. (B, C) In both TCGA and MSKCC cohorts, expression level of miR-326 in tumor and normal tissues (D) CKAP2L mRNA is negatively associated with miR-326. (E) Expression of miR-326 in BPH-1, 22Rv1, C4-2, PC-3, DU145 and LNCaP-AI cell lines. (F) miR-326 expression after mimic miR-326 transfected in PC-3 and LNCaP-AI cells. (G) CKAP2L mRNA and protein expression in mimic miR-326 transfected PC-3 and LNCaP-AI cells. (H, I) Dual-luciferase assay was performed to verify the binding relationship between CKAP2L mRNA and miR-326. (J, K) RIP was conducted to demonstrate that miR-326 directly interacts with CKAP2L mRNA binding sites. The comparison was between the igG and Ago2. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001